Researchers conducted a retrospective analysis of the Premier Healthcare Database from January 2011 to April 2017. They examined 12,589 patients.
Patients receiving Exparel decreased their postsurgical inpatient opioid use, decreased their length of stay by 0.7 days, and had a 1.6- to 1.7-fold higher chance of a home discharge than those who didn’t receive Exparel. Exparel patients also faced no increased readmission risk.
Exparel reduced hospitalization costs by $561 in Medicare populations but increased costs in commercial populations by $41.
More articles on orthopedics:
Orthopedic institute opens new specialty clinic in California — 4 details
Novant Health opens orthopedic, spine office in Supply — 3 insights
Orthopedic rehab center to open in Tennessee: 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
